Physician profile
Armin Marefat
NPI 1629291000
$1,258.36
in general payments reported to CMS, 2019-2025
25 companies · $110 in 2025
The $110 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24.47 · 2021: $57.53 · 2022: $31.39 · 2023: $650 · 2024: $385 · 2025: $110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,144.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $248.45 | 2021-2025 | |
| Janssen Biotech, INC. | $137.89 | 2022-2024 | Stelara |
| Celgene Corporation | $113.11 | 2023-2024 | Zeposia |
| Csl Behring | $82.01 | 2024-2025 | Haegarda, Hizentra |
| Genzyme Corporation | $76.98 | 2023-2024 | |
| Regeneron Healthcare Solutions, INC. | $69.06 | 2023 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $62.09 | 2021-2023 | Xifaxan |
| Ferring Pharmaceuticals INC. | $56.81 | 2023 | Rebyota |
| Ironwood Pharmaceuticals, INC | $46.67 | 2023 | Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $40.83 | 2019-2023 | Gattex |
| Pfizer INC. | $36.43 | 2023 | |
| Ardelyx, INC. | $36.19 | 2023 | Ibsrela |
| Biocryst US Sales Co., LLC | $32.75 | 2025 | Orladeyo |
| Qol Medical, LLC | $23.76 | 2024 | Sucraid |
| Phathom Pharmaceuticals, INC. | $21.85 | 2024-2025 | Voquezna |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $20.67 | 2023 | Ocaliva |
| Merck Sharp & Dohme LLC | $18.78 | 2023 | Dificid |
| E.R. Squibb & Sons, L.L.C. | $18.71 | 2023 | |
| Sandoz INC. | $18.63 | 2024 | Hyrimoz |
| Ipsen Biopharmaceuticals, INC | $18.49 | 2024 | |
| Nestle Healthcare Nutrition INC. | $17.78 | 2023 | |
| Fresenius Kabi USA, LLC | $16.85 | 2024 | Idacio |
| Madrigal Pharmaceuticals | $16.44 | 2025 | Rezdiffra |
| Daiichi Sankyo INC. | $16.00 | 2022 | |
| Olympus America INC. | $11.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Armin Marefat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.